David R. Lally, MD: Analyzing Nascent GA, Intermediate AMD Progression from GATHER1
Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.
Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME
Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.
Optogenetics Product Provides Safe Treatment Opportunity for Retinitis Pigmentosa Reversal
An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.
Julia A Haller, MD: Facing Challenges and Finding Solutions in Retina
Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.
Dosing Variability Risk Could Be High With Aflibercept PFS
An AAO 2021 presentation highlighted the industrial design differences that could result in treatment overdoses with pre-filled syringes of aflibercept.
COVID-19 Lockdowns Drove Fewer Anti-VEGF Injections, Worse Vision in Ophthalmic Patients
Early 2020 response to the pandemic was linked to many patients being lost to follow-up, and countries reported worse overall visual acuity among their patients.
Reduced Retinal Fluid Linked to Better nAMD Visual Improvements
New HAWK and HARRIER findings show patients with fluid-free visits reported greater benefit in BVCA while receiving anti-VEGF.
Thoughts on AAO 2020: Uveitis Subspecialty Day
A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.
Raymond Douglas, MD, PhD: The Shift to Telemedicine in Ophthalmology
Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.
Development of Geographic Atrophy is Similar Across Ranibizumab Dosing Regimens
A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.
New Study Examines Role of Anti-VEGF Injections on Treatment Patterns
There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.
PRN Injections Yields Improvements for Diabetic Retinopathy Patients
In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.
Ranibizumab Associated with Improved Choroid Flow in DME
A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.
Nadia Waheed, MD, MPH: OCT Angiography Predicts DR Progression
A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.
Ehsan Rahimy, MD: The Importance of Continued Geographic Atrophy Screening
A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.
Registry Shows Preferences for Invasive Procedures in Pediatric Retinal Detachments
RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.
Diabetes Could Influence Glaucoma Patient Microvascular Density
Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.
Geeta Lalchandani-Lalwani, MD: Screening, Treatment of Diabetic Retinopathy
Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.
Ranibizumab Biosimilar Shows Similar Efficacy through 48 Weeks
A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.
Geeta Lalchandani-Lalwani, MD: Diabetic Retinopathy Progression in a Large Dataset
For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.
Aflibercept Benefits Macular Edema Visual Acuity at 2 Years
Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.
Single-Cell RNA Sequencing May Improve Personalized Uveitis Therapy
Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.
Premature Infant Retinopathy Regression More Prevalent in Females, Minorities
New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.
Anti-VEGF Injections Increases the Risk of Open-Angle Glaucoma
In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.
Women, Asian, Comorbid Patients with Myopia Face Worse Retinal Detachment Risk
New AAO 2020 findings suggest even geographical differences could define retinal detachment risks among nearsighted patients.
Investigational Drug Shows Promise Treating Wet AMD
In data presented at AAO, investigators find BI 836680 shows early signals of bioactivity.
Fundus Images Useful in Detecting Hypertension And Diabetes
In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.
New Data Shows Promise for Investigative XLRP Gene Therapy
The study presented at AAO provides an update on previously shared 6-month data from earlier this year.
Raymond Douglas, MD, PhD: Teprotumumab for Thyroid Eye Disease Provides Long-Term Benefit
Raymond Douglas, MD, PhD, discusses data that demonstrate the benefit of teprotumumab in patients with all levels of thyroid eye disease.
Edmund Tsui, MD: A Discussion on AAO 2020 Virtual
Edmund Tsui, MD, talks the new AAO 2020 virtual format as well as presentations that have particularly caught his attention.
